Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-16-026955.pdf
0001179110-16-026955.rtf
0001179110-16-026955.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-16-026950.pdf
0001179110-16-026950.rtf
0001179110-16-026950.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-16-026951.pdf
0001179110-16-026951.rtf
0001179110-16-026951.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-16-006478.pdf
0001558370-16-006478.rtf
0001558370-16-006478.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-16-026165.pdf
0001179110-16-026165.rtf
0001179110-16-026165.xls
UPLOAD

UPLOAD

 View HTML
0000000000-16-076961.pdf
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-16-005749.pdf
0001558370-16-005749.rtf
0001558370-16-005749.xls
10-Q

Quarterly report which provides a continuing view of a company's financial position

 View HTML
0001558370-16-005818.pdf
0001558370-16-005818.rtf
0001558370-16-005818.xls
EX-101.INS - EX-101.INS
S-3

Simplified registration form

 View HTML
0001558370-16-005826.pdf
0001558370-16-005826.rtf
0001558370-16-005826.xls
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000921895-16-004320.pdf
0000921895-16-004320.rtf
0000921895-16-004320.xls